A fundamental analysis of Apollo Hospitals Enterprises Ltd. (APOLLOHOSP) covering revenue trends, profitability, valuation, and shareholding patterns.
Apollo Hospitals Revenue Trend
Apollo Hospitals Enterprises Ltd. managed to grow its top line 14.8% in FY2025, with revenue hitting ₹21,994 Cr.
A 15.6% revenue CAGR over 10 years is hard to ignore. Apollo Hospitals Enterprises Ltd.'s top line moved from ₹5,178 Cr to ₹21,994 Cr in that period.
Apollo Hospitals Enterprises Ltd.'s ₹21,994 Cr revenue base puts it in the major bracket among healthcare companies in India.
The consistency stands out: 4 consecutive years of growth in top-line revenue.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹21,994 Cr | +14.8% |
| FY2024 | ₹19,166 Cr | +14.7% |
| FY2023 | ₹16,703 Cr | +13.3% |
| FY2022 | ₹14,741 Cr | +39.0% |
| FY2021 | ₹10,605 Cr | — |
View Apollo Hospitals Enterprises Ltd.'s full 10-year revenue trend with CAGR analysis →
Apollo Hospitals Profitability
Year-over-year, net profit grew 61.0% from ₹935 Cr to ₹1,505 Cr in FY2025 for Apollo Hospitals Enterprises Ltd..
A stronger net margin of 6.8% in FY2025 (from 4.9%) points to better profitability per rupee of revenue.
The diluted EPS figure moved up to ₹100.56 in FY2025, against ₹62.50 posted in FY2024.
Is Apollo Hospitals Undervalued
Using the P/E Ratio methodology, the calculated intrinsic value comes to ₹8,684.
Apollo Hospitals Enterprises Ltd. shares are currently trading at ₹8,782.50.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹8,684 | 1.1% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Apollo Hospitals Enterprises Ltd. with detailed assumptions →
Apollo Hospitals Shareholding Pattern
At 28.0%, the promoter stake has been flat for the past 4 quarters.
Foreign investors held 41.5% of the company as of June 2026, down year-over-year from 44.2%.
Domestic investors held 23.7% of the company as of June 2026, up year-over-year from 21.1%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 28.0% | 41.5% | 23.7% | 6.5% |
| Mar 2026 | 28.0% | 42.6% | 22.8% | 6.4% |
| Dec 2025 | 28.0% | 43.5% | 21.5% | 6.7% |
| Sep 2025 | 28.0% | 44.2% | 21.1% | 6.4% |
Track quarterly shareholding changes for Apollo Hospitals Enterprises Ltd. →
Apollo Hospitals Balance Sheet
Proportional view as of 13 Jul 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹206.57B at the end of FY2025, up 23.3% from ₹167.53B a year earlier.
Property, Plant & Equipment is the largest block at 39.3%, followed by Other Assets at 22.5% and Receivables at 14.6%.
Equity makes up 41.9% of liabilities and equity, with debt at 38.1% and operating liabilities at 20.0%. Over the year, debt is up 47.5% and equity is up 18.2%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 20.10B |
| Receivables | 30.16B |
| Inventories | 4.81B |
| Property, Plant & Equipment | 81.21B |
| Investments | 10.55B |
| Intangibles & Goodwill | 13.20B |
| Other Assets | 46.55B |
| Category | Value |
|---|---|
| Equity | 86.53B |
| Short-term Debt | 10.33B |
| Long-term Debt | 68.31B |
| Trade Payables | 22.41B |
| Other Liabilities | 19.00B |
What Stands Out About Apollo Hospitals
What should investors take away from Apollo Hospitals Enterprises Ltd.'s (APOLLOHOSP) latest numbers? Here's the summary.
Revenue of ₹21,994 Cr in FY2025, up 14.8% year-over-year.
Long-term revenue has been compounding at 15.6% annually over 10 years.
The company is profitable, with a net margin of 6.8% and net income of ₹1,505 Cr.
The P/E Ratio model implies 1.1% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Craytheon's full analysis of Apollo Hospitals Enterprises Ltd. goes deeper: three valuation models, growth metrics, and 10 years of financial data.